The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
Open accessAbstract
Background—: Homozygous familial hypercholesterolemia is an inherited disorder caused by mutations in both low-density lipoprotein receptor alleles, which results in extremely elevated plasma low-density lipoprotein cholesterol concentrations and very early morbidity and mortality due to cardiovascular disease. Methods and Results—: To evaluate the impact of advances in lipid-lowering (predominantly statin) therapy on cardiovascular disease morbidity and mortality in a large cohort of patients with homozygous familial hypercholesterolemia, the records of 149 patients (81 females, 68 males) from 2 specialized lipid clinics in South Africa were evaluated retrospectively. Homozygous familial hypercholesterolemia was diagnosed by confirmation of mutations in genes affecting low-density lipoprotein cholesterol or by clinical criteria. A Cox proportional hazard model with time-varying exposure was used to estimate the risk of death and major adverse cardiovascular events among statin-treated patients compared with statin-naive patients. The hazard ratio for benefit from lipid therapy, calculated with the Cox proportional hazards model for the end point of death, was 0.34 (95% confidence interval 0.14–0.86; P =0.02), and for the end point of major adverse cardiovascular events, it was 0.49 (95% confidence interval 0.22–1.07; P =0.07). This occurred despite a mean reduction in low-density lipoprotein cholesterol of only 26.4% (from 15.9±3.9 to 11.7±3.4 mmol/L; P <0.0001) with lipid-lowering therapy. Conclusions—: Lipid-lowering therapy is associated with delayed cardiovascular events and prolonged survival in patients with homozygous familial hypercholesterolemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,276
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Self-citationEfficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES
Slack, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90930-1 · Cited by 623
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18925 · Cited by 560
Gagné, C., Gaudet, D., & Bruckert, E. (2002) · Circulation · doi:10.1161/01.cir.0000018744.58460.62 · Cited by 482
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn422 · Cited by 425
Mabuchi, H., Koizumi, J., Shimizu, M., Kajinami, K., Miyamoto, S., Ueda, K., & Takegoshi, T. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00692-4 · Cited by 293
Lowering LDL—not only how low, but how long?
Brown, M. S., & Goldstein, J. L. (2006) · Science · doi:10.1126/science.1125884 · Cited by 204
A host of hypercholesterolaemic homozygotes in South Africa.
Seftel, H. C., Baker, S. G., Sandler, M. P., Forman, M. B., Joffe, B. I., Mendelsohn, D., Jenkins, T., & Mieny, C. J. (1980) · BMJ · doi:10.1136/bmj.281.6241.633 · Cited by 153
The Molecular Mechanism for the Genetic Disorder Familial Defective Apolipoprotein B100
Borén, J., Ekström, U., Agren, B., Nilsson‐Ehle, P., & Innerarity, T. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008890200 · Cited by 147
Heath, K. E. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00647-x · Cited by 122
Vascular Calcifications in Homozygote Familial Hypercholesterolemia
Awan, Z. A., Al‐Rasadi, K., Francis, G. A., Hegele, R. A., McPherson, R., Frohlich, J., Valenti, D. A., de Varennes, B., Marcil, M., Gagné, C., et al. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.160408 · Cited by 98
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia
Raal, F. J., Pilcher, G. J., Illingworth, D. R., Pappu, A. S., Stein, E. A., Laskarzewski, P. M., Mitchel, Y., & Melino, M. R. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00168-8 · Cited by 97
Self-citationInhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia
Raal, F. J., Pappu, A. S., Illingworth, D. R., Pilcher, G. J., Marais, A. D., Firth, J. C., Kotze, M. J., Heinonen, T. M., & Black, D. M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00435-9 · Cited by 96
Self-citationMarais, A. D., Raal, F. J., Stein, E. A., Rader, D. J., Blasetto, J. W., Palmer, M. K., & Wilpshaar, W. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.06.028 · Cited by 90
Self-citationLópez-Santamaría, M. M., Migliazza, L., Gámez, M., et al. (2000) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2000.0350630 · Cited by 57
Kotze, M. J., Theart, L., Callis, M., Peeters, A. V., Thiart, R., & Langenhoven, E. (1995) · Genome Research · doi:10.1101/gr.4.6.352 · Cited by 52
Thompson, G. R. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833e13fd · Cited by 48
Statins in homozygous familial hypercholesterolemia
Marais, A. D., Blom, D. J., & Firth, J. C. (2002) · Current Atherosclerosis Reports · doi:10.1007/s11883-002-0058-7 · Cited by 40
Self-citationOther Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
Stein, E. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.011 · Cited by 34
Rubinsztein, D., Coetzee, G. A., Marais, A., Leitersdorf, E., Seftel, H. C., & van der Westhuyzen, D. R. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41387-2 · Cited by 25
Self-citationAbera, A. B., Marais, A. D., Raal, F. J., Leisegang, F., Jones, S., George, P. M., & Henderson, H. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.10.005 · Cited by 12
Self-citation
Cited by
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationWiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv157 · Cited by 891
“In retrospective studies, both approaches have delayed cardiovascular events and increased survival.(122,123) Despite the”
BackgroundSelf-citationKinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744
Self-citation
Metadata
- Authors
- Raal, F. J., Pilcher, G. J., Panz, V. R., van Deventer, H. E., Brice, B. C., Blom, D. J., & Marais, A. D.
- Venue
- Circulation
- Published
- 2011-11-15
- Volume
- 124
- Issue
- 20
- Pages
- 2202-2207
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2026205222
- Cited by
- 366
- References
- 32
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.